Table 6. Analysis of association between predicted̂ TGF β signaling strength and risk for breast cancer.

	Maharashtrian Subjects			Parsi Subjects
	Cases/Controls	OR† (95% CI)	OR‡ (95% CI)	Cases/Controls	OR† (95% CI)
Predicted Signaling Status
Dominant Model
HS	29/52	1	1	2/32	1
IS + LS	128/167	1.37 (0.83-2.29)	1.27 (0.74-2.2)	40/128	5 (1.15-21.79)*
Additive Model
HS	29/52	1	1	2/32	1
IS	126/160	1.41 (0.85-2.35)	1.29 (0.75-2.24)	31/111	4.47 (1.01-19.69)*
LS	2/7	0.51 (0.1-2.63)	0.66 (0.12-3.71)	9/17	8.47 (1.64-43.72)*
Recessive Model
HS + IS	155/212	1	1	33/143	1
LS	2/7	0.39 (0.08-1.91)	0.54 (0.10-2.87)	9/17	2.29 (0.94-5.59)

^†Crude ORs;

^‡Age adjusted ORs;

*p≤0.05;

**p≤0.01.

HS - High Signalers: CC/9A9A; IS - Intermediate Signalers: TT/9A9A, CC/9A6A, CC/6A6A or TC/9A9A;

LS - Low Signalers: TT/6A6A, TT/9A6A, TC/9A6A or TC/6A6A ^(Ref. 30).